NO980218L - p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling - Google Patents

p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling

Info

Publication number
NO980218L
NO980218L NO980218A NO980218A NO980218L NO 980218 L NO980218 L NO 980218L NO 980218 A NO980218 A NO 980218A NO 980218 A NO980218 A NO 980218A NO 980218 L NO980218 L NO 980218L
Authority
NO
Norway
Prior art keywords
expression constructs
expression
cancer treatment
transcript
replication
Prior art date
Application number
NO980218A
Other languages
English (en)
Norwegian (no)
Other versions
NO980218D0 (no
Inventor
Xiaomei Jin
Jack Roth
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO980218D0 publication Critical patent/NO980218D0/no
Publication of NO980218L publication Critical patent/NO980218L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO980218A 1995-07-17 1998-01-16 p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling NO980218L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50288195A 1995-07-17 1995-07-17
PCT/US1996/011787 WO1997003635A2 (en) 1995-07-17 1996-07-17 p16 EXPRESSION CONSTRUCTS AND THEIR APPLICATION IN CANCER THERAPY

Publications (2)

Publication Number Publication Date
NO980218D0 NO980218D0 (no) 1998-01-16
NO980218L true NO980218L (no) 1998-03-16

Family

ID=23999797

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980218A NO980218L (no) 1995-07-17 1998-01-16 p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling

Country Status (15)

Country Link
US (1) US6251871B1 (hu)
EP (1) EP0839207A2 (hu)
JP (1) JPH11510380A (hu)
KR (1) KR19990029028A (hu)
CN (1) CN1203632A (hu)
AU (1) AU724324B2 (hu)
BR (1) BR9609853A (hu)
CA (1) CA2227193A1 (hu)
CZ (1) CZ15498A3 (hu)
HU (1) HUP9901908A3 (hu)
NO (1) NO980218L (hu)
NZ (1) NZ313828A (hu)
PL (1) PL324750A1 (hu)
SK (1) SK6598A3 (hu)
WO (1) WO1997003635A2 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
US7163925B1 (en) * 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
CA2234060A1 (en) † 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
WO1998037190A1 (en) * 1997-02-20 1998-08-27 Hepavec Aktiengesellschaft Für Gentherapie Method for induction of apoptotic cell death in malignant cells, through reduction of the rb to apoptosis inducing proteins ratio
DK0966206T3 (da) 1997-03-14 2005-07-25 Unilever Nv Frossent födevareprodukt indeholdende antifrysepeptider
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
KR19990086165A (ko) * 1998-05-26 1999-12-15 성재갑 Cdk４ 의 저해제인 p16의 카복시말단이 절단된 결손형cδp１６ 단백질, 그의 유전자
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
CN101507822B (zh) 2003-11-24 2012-06-06 坎吉有限公司 皮肤瘢痕形成的减少
AU2005276231A1 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases
US7695965B2 (en) * 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
CN103293308B (zh) * 2013-05-24 2014-11-26 尉军 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用
CN104558147B (zh) * 2015-01-20 2017-11-07 刘林林 一种检测宫颈癌标志物cdkn2a抗原表位多肽及应用
WO2016183597A1 (en) 2015-05-14 2016-11-17 Expression Pathology, Inc. Srm/mrm assay for the fibroblast growth factor receptor 2 (fgfr2) protein
JP6600697B2 (ja) 2015-05-22 2019-10-30 エクスプレッション、パソロジー、インコーポレイテッド サイクリン依存性キナーゼ阻害剤２Ａ（ｐ１６）タンパク質のためのＳＲＭ／ＭＲＭアッセイ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
PT665886E (pt) 1992-10-16 2003-10-31 Cold Spring Harbor Lab Rearranjo de complexos de ciclina e suas utilizacoes
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
MY119195A (en) * 1993-12-30 2005-04-30 Shell Int Research Lightweight, wide-bodied compliant tower.
NZ284612A (en) 1994-03-18 1997-09-22 Univ Utah Res Found Multiple tumour suppressor (mts) gene and its use in the diagnosis and treatment of cancer
WO1995025429A1 (en) 1994-03-18 1995-09-28 Myriad Genetics, Inc. Mts gene, mutations therein, and methods for diagnosing cancer using mts gene sequence
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
WO1995030002A2 (en) 1994-04-29 1995-11-09 San Diego Regional Cancer Center Enhancing the sensitivity of tumor cells to therapies
DE19501073A1 (de) * 1995-01-16 1996-08-01 Nova C O R D Ag Bildverarbeitungsverfahren zur Ermittlung der Strukturfestigkeit eines Prüfobjektes mit diffus streuender Oberfläche
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
AU737621B2 (en) 1997-02-18 2001-08-23 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
CZ15498A3 (cs) 1998-07-15
AU6647896A (en) 1997-02-18
US6251871B1 (en) 2001-06-26
NZ313828A (en) 1999-02-25
PL324750A1 (en) 1998-06-08
JPH11510380A (ja) 1999-09-14
BR9609853A (pt) 1999-10-13
SK6598A3 (en) 1998-09-09
CA2227193A1 (en) 1997-02-06
WO1997003635A2 (en) 1997-02-06
AU724324B2 (en) 2000-09-14
WO1997003635A3 (en) 1997-05-15
HUP9901908A3 (en) 2000-02-28
KR19990029028A (ko) 1999-04-15
NO980218D0 (no) 1998-01-16
CN1203632A (zh) 1998-12-30
EP0839207A2 (en) 1998-05-06
HUP9901908A2 (hu) 1999-09-28

Similar Documents

Publication Publication Date Title
NO980218L (no) p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling
GEP20012500B (en) Inhibitors of Protein Farnesyl Transferase
DK0556345T3 (da) Retrovirale vektorer,som er egnede til genterapi
MX9708401A (es) Genes reguladores de la cromatina.
FI973467A0 (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
EP1126034A3 (en) Coding sequences of the human BRCA1 gene
EP1017797A4 (en) NON-ORIGINATING PRIMATE LENTIVIRUS VECTORS AND PACKAGING SYSTEMS
NO975557D0 (no) Immortalisering og dismortalisering av celler
ATE205532T1 (de) Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper
WO1998037185A3 (en) Vectors for controlled gene expression
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
AU6120600A (en) Herpes simplex virus expressing foreign genes and method for treating cancers therewith
DK0843731T3 (da) Adenovirusvektorer til genterapi
EP1070122A4 (en) INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES
DE59604375D1 (de) Leberspezifischer adenovirus-expressionsvektor
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
NO20002412D0 (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
ATE248914T1 (de) Allogenes vakzin und synthesemethode für selbiges
AU4096100A (en) Pseudotyped retroviral vector for gene therapy of cancer
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
ATE297409T1 (de) In krebszellen überexprimiertes genprodukt
AU4644297A (en) Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene
NO973421L (no) Rekombinant DNA omfattende DNA som koder for myosin tungkjede SM1-isoformt protein innskutt i vektor DNA, mikroorganisme som inneholder det rekombinante DNA og et middel for behandling av arteriosklerose omfattende det rekombinante DNA
WO2001098350A3 (en) Compositions comprising net-4 modulations and their use for treating neoplastic disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application